Enanta Pharma (ENTA) Tops Q3 EPS by 4c. Revs Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Enanta Pharmaceuticals (ENTA) PT Raised to $38 at JPMorgan
August 8, 2017 8:45 AM EDTJPMorgan raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $38.00 (from $32.00) while maintaining a Overweight rating.
... MoreEnanta Pharmaceuticals (ENTA) PT Raised to $36 at Baird; Remains Sidelined
August 8, 2017 7:19 AM EDTBaird raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $36.00 (from $27.00) while maintaining a Neutral rating following the company's 3Q. AbbVie's reported sales of $225M for Viekira were largely in line with estimates. Enanta earned $7.5M in royalty revenue on these sales, versus... More
